These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An update on Zika vaccine developments. Durbin A; Wilder-Smith A Expert Rev Vaccines; 2017 Aug; 16(8):781-787. PubMed ID: 28633549 [TBL] [Abstract][Full Text] [Related]
4. Challenges of Vaccine Development for Zika Virus. Blackman MA; Kim IJ; Lin JS; Thomas SJ Viral Immunol; 2018 Mar; 31(2):117-123. PubMed ID: 29227202 [TBL] [Abstract][Full Text] [Related]
5. Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus. Kudchodkar SB; Choi H; Reuschel EL; Esquivel R; Jin-Ah Kwon J; Jeong M; Maslow JN; Reed CC; White S; Kim JJ; Kobinger GP; Tebas P; Weiner DB; Muthumani K Microbes Infect; 2018 Dec; 20(11-12):676-684. PubMed ID: 29555345 [TBL] [Abstract][Full Text] [Related]
6. A Live-Attenuated Zika Virus Vaccine with High Production Capacity Confers Effective Protection in Neonatal Mice. Ye X; Liu X; Shu T; Deng W; Liao M; Zheng Y; Zheng X; Zhang X; Li T; Fan W; Qu L; Chen L; Li F; Feng L J Virol; 2021 Jun; 95(14):e0038321. PubMed ID: 33910950 [TBL] [Abstract][Full Text] [Related]
7. Zika Virus Vaccine Development: Progress in the Face of New Challenges. Diamond MS; Ledgerwood JE; Pierson TC Annu Rev Med; 2019 Jan; 70():121-135. PubMed ID: 30388054 [TBL] [Abstract][Full Text] [Related]
8. Zika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse Models. Li P; Ke X; Wang T; Tan Z; Luo D; Miao Y; Sun J; Zhang Y; Liu Y; Hu Q; Xu F; Wang H; Zheng Z J Virol; 2018 Sep; 92(17):. PubMed ID: 29925661 [TBL] [Abstract][Full Text] [Related]
9. Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection. Yau C; Gan ES; Kwek SS; Tan HC; Ong EZ; Hamis NZ; Rivino L; Chan KR; Watanabe S; Vasudevan SG; Ooi EE EBioMedicine; 2020 Nov; 61():103028. PubMed ID: 33045466 [TBL] [Abstract][Full Text] [Related]
11. Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone. Li XF; Dong HL; Wang HJ; Huang XY; Qiu YF; Ji X; Ye Q; Li C; Liu Y; Deng YQ; Jiang T; Cheng G; Zhang FC; Davidson AD; Song YJ; Shi PY; Qin CF Nat Commun; 2018 Feb; 9(1):673. PubMed ID: 29445153 [TBL] [Abstract][Full Text] [Related]
15. The emergence of Zika virus and its new clinical syndromes. Pierson TC; Diamond MS Nature; 2018 Aug; 560(7720):573-581. PubMed ID: 30158602 [TBL] [Abstract][Full Text] [Related]
16. Single dose of chimeric dengue-2/Zika vaccine candidate protects mice and non-human primates against Zika virus. Baldwin WR; Giebler HA; Stovall JL; Young G; Bohning KJ; Dean HJ; Livengood JA; Huang CY Nat Commun; 2021 Dec; 12(1):7320. PubMed ID: 34916486 [TBL] [Abstract][Full Text] [Related]
17. A systematic approach to the development of a safe live attenuated Zika vaccine. Kwek SS; Watanabe S; Chan KR; Ong EZ; Tan HC; Ng WC; Nguyen MTX; Gan ES; Zhang SL; Chan KWK; Tan JH; Sessions OM; Manuel M; Pompon J; Chua C; Hazirah S; Tryggvason K; Vasudevan SG; Ooi EE Nat Commun; 2018 Mar; 9(1):1031. PubMed ID: 29531213 [TBL] [Abstract][Full Text] [Related]